Korro Bio, Inc. last reported quarterly results on Nov 5, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $0 (-100.0% year over year) and diluted EPS of -$0.98. It usually reports 36–68 days after a quarter ends. Based on that pattern, the next release is estimated for around Mar 8, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Mar 9, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 36–68 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 5, 2026
36 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
0
-100.0%
|
-18
+2.8%
|
-0.98
+49.0%
|
|
Aug 6, 2026
37 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
0
-100.0%
|
-19
+26.6%
|
-1.07
+60.9%
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
0
-100.0%
|
-20
+16.1%
|
-1.69
+32.1%
|
|
Mar 9, 2026
68 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
1
|
-50
-136.1%
|
-5.32
-134.7%
|
|
Nov 12, 2025
43 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
1
|
-18
+14.0%
|
-1.92
+15.0%
|
|
Aug 12, 2025
43 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
1
|
-26
-18.1%
|
-2.74
-12.8%
|
|
May 7, 2025
37 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
3
|
-23
-19.6%
|
-2.49
-2.0%
|
|
Nov 12, 2024
43 days after quarter end
|
—
ended Sep 30, 2024
|
—
|
—
|
—
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KRRO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1703647
- Former names
- Frequency Therapeutics, Inc. (until Nov 6, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.